Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a factor VIII protein, wherein a B domain portion of the factor VIII protein is encoded by a nucleotides sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

Abstract: A method of transferring a single metal atom from a first location to a second location on the surface of a metal oxide is disclosed. The method includes obtaining a material having a first metal atom deposited on a first oxygen atom vacancy of the metal oxide and transferring the first metal atom of the metal on the first oxygen atom vacancy to a second location on the metal oxide by applying a voltage to the first metal atom. The second location can be a second metal atom on a second oxygen atom vacancy of the metal oxide, where the first and second metal atoms form a first metal atom-second metal atom species, or a metal atom of the metal oxide, where the first metal atom and the metal atom of the metal oxide forms a first metal atom-metal atom of the metal oxide species.

Abstract: The present invention relates to sulfonium salts of formula (I): (I), their preparation, and utility as precursors for preparing functionalized organic compounds, wherein R1 and R2 are the same or different and each is independently selected from an optionally substituted aryl group, an optionally substituted alkynyl group, an optionally substituted alkenyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkenyl group, an optionally substituted aralkyl group, an optionally substituted arylalkenyl group, an optionally substituted heteroaryl group, an optionally substituted heterocyclyl group, an optionally substituted amine, an optionally substituted alkoxy group, an optionally substituted thioether group, an optionally substituted phosphine group, an optionally substituted boron species, an optionally substituted carbene, an organometallic moiety, and a halide, or R1 and R2 are joined together to form an optionally substituted sulfur-con

Abstract: A method and an apparatus are provided for building a subject-specific statistical model of shape variation for an anatomical structure using a set of geometric representations of shape for the anatomical structure. Each representation is associated with one of multiple subjects, each subject having a respective subset of associated representations, and each subset comprising multiple representations including a reference representation. The multiple representations correspond to different shapes of the anatomical structure arising from physical motion and/or deformation thereof. The method comprises specifying a set of shape parameters whose values, for any given representation, characterize the shape of the representation, and for each subject, representing a probability distribution of the values of the shape parameters across the subset of representations associated with that subject by a set of subject-specific distribution parameters.

Abstract: The present invention provides a chimeric protein having the formula: Casp-Ht1-Ht2 wherein Casp is a caspase domain; Ht1 is a first heterodimerization domain; and Ht2 is a second heterodimerization domain and wherein, in the presence of a chemical inducer of dimerization (CID), an identical pair of the chimeric proteins interact such that Ht1 from one chimeric protein heterodimerizes with Ht2 from the other chimeric protein, causing homodimerization of the two caspase domains. The invention also provides a cell comprising such a protein and its use in adoptive cell therapy.

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Abstract: The present invention concerns a conjugate of a domain I ?2GP1 polypeptide with a water-soluble polymer, wherein the polymer is bound via two cysteine residues derived from a disulfide bridge in the domain I ?2GP1 polypeptide.

Abstract: The present invention relates to methods and materials for treating an individual with KRAS-mutated cancer or a cancer in which ROCK is inhibited independently of mutated KRAS. The invention is based on the prevention or disruption of the binding of TRAIL-Receptor to its ligand, TRAIL, in vivo, for example by use of an agent that neutralizes TRAIL and/or a the TRAIL-Receptor (such TRAIL-R2) and/or diminishes TRAIL/TRAIL-Receptor activity, thereby reducing cancer cell transformation, migration and metastasis, prolonging survival of patients.

Abstract: A micromechanical device has a functional layer. One or more layers are provided between the functional layer and the micromechanical device to provide stress relief.

Abstract: The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of cardiovascular disease or of an inflammatory disease or condition: wherein: V is N or CR3; X is N or CR4; Y is N or CR5; Z is N or CR6; B is —(C?O)R1, a 5- to 10-membered heteroaryl group, or a group L??-NRR?, wherein R and R? are the same or different and each represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group; R1 is a 5- to 10-membered heterocyclyl group, or —OR?, wherein R? is a hydrogen atom, a C1-C6 alkyl group or a C1-C6 haloalkyl group, or R1 is a proteinogenic ? amino acid, which is linked to the carbonyl moiety in the compound of formula (I) via the ? amino group, which amino acid is optionally esterified at the ? carboxylic acid group with a C1-C6 alkyl group or a C6-C10 aryl group, or R1 is —NR?R??, —NRIV-L??-CONR?R??, or —NRIV-L??-COOR, wherein R, R?, R?? and RIV are the same or different and e

Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of SEQ ID NO. 1. Also described are: vectors comprising the nucleic acid molecule for expressing the preproinsulin protein; host cells comprising the nucleic acid molecule or a vector; a transgenic animal comprising cells comprising the nucleic acid molecule or the vector; a pharmaceutical composition comprising the nucleic acid molecule or the vector; a method of treating diabetes comprising administering a therapeutically effective amount of the vector to a patient suffering from diabetes; the nucleic acid molecule for use in therapy; and the nucleic acid molecule or the vector for use in the treatment of diabetes.

Abstract: Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (HSCs), such as non-alcoholic fatty liver disease (NAFLD), fibrosis, and liver cancer, using ammonia-lowering therapies.

Abstract: The present invention concerns compounds for use in the prevention of viral replication and/or the prevention or treatment of a viral infection, wherein the compounds are selective inhibitors of inducible nitric oxide synthase, and methods of preventing viral replication and/or preventing or treating viral infections in a subject comprising administering a prophylactically or therapeutically effective amount of the compounds.

Abstract: The present invention relates to a linker for forming conjugates of a protein or peptide with a therapeutically active agent and which comprise a thiomaleamic acid moiety that is susceptible to cleavage under the pH conditions prevalent in the lysosome.

Abstract: A method for producing an engineered tissue scaffold for neural repair is described. The method includes tethering a hydrogel matrix seeded with tension-generating cells to a frame, and allowing the tension-generating cells to generate tension within the matrix, such that the cells self-align. The matrix may then be at least partially dehydrated to form a sheet. The tension-generating cells are stem cells capable of differentiating into cells having Schwann-cell-like properties, or are derived from such stem cells. In preferred embodiments, the cells are neural stem cells, for example conditionally immortalized neural stem cells of fetal cortex origin.

Abstract: A method and apparatus are provided for registering pre-operative three dimensional (3-D) image data of a deformable organ comprising vessels with multiple intra-operative two-dimensional (2-D) ultrasound images of the deformable organ acquired by a laparoscopic ultrasound probe during a laparoscopic procedure. The apparatus is configured to: generate a 3-D vessel graph from the 3-D pre-operative image data; use the multiple 2-D ultrasound images to identify 3-D vessel locations in the deformable organ; determine a rigid registration between the 3-D vessel graph from the 3-D pre-operative image data and the identified 3-D vessel locations in the deformable organ; and apply said rigid registration to align the pre-operative three dimensional (3-D) image data with the two-dimensional (2-D) ultrasound images, wherein the rigid registration is locally valid in the region of the deformable organ of interest for the laparoscopic procedure.

Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional ?-galactosidase A protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described is a vector, host cell or transgenic animal comprising the nucleic acid molecule; and a pharmaceutical composition comprising the nucleic acid molecule or the vector. Further, the use of the nucleic acid molecule in a method of treating Fabry disease is described.

Abstract: A fuel cell comprising at least two stacked fuel cell boards (22) which each comprise a membrane of substantially gas impervious electrolyte material and at least two electrode pairs wherein the anode and cathode of each said electrode pair are arranged on respective faces of said membrane. An electrode of each pair of electrodes is connected to an electrode of an adjacent pair of electrodes by a through-membrane connection (13) or by an external connection on a Printed Circuit Board, comprising an electrically conductive region of said electrolyte material. A method for forming the through-membrane electrical connections in the electrolyte membrane is also disclosed.

Abstract: A method of X-ray imaging includes passing an X-ray beam through a pre-sample mask 8 with a plurality of apertures 32, through a sample 10, and then through a detector mask 6 with aligned apertures 34. The beams are detected. The detector mask 6 and pre-sample mask 8 are moved with respect to one another to identify the position of maximum intensity and then moved to two further positions on equal and opposite spacings on either side of the maximum. Images are acquired and a transmission image, refraction image and scattering image calculated.

Abstract: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ?m or less.